About AlveoliX
AlveoliX is a Healthcare company based in Bern (Switzerland) founded in 2015. AlveoliX offers products and services including AX Barrier-on-Chip System, AX Lung-on-Chip System, and AX Biomodels. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Microfluidics. Its legal entity is AlveoliX AG.
Company details
Developer of organ-on-chip technologies to enable more efficient drug development. The lead product Lung-on-Chip system is an in-vitro model that closely mimics the biophysical characteristics of the lung, including the mechanical stress induced by respiration. This model is expected to best predict the effects of respiratory drug candidates in humans.
- Headquarters Bern, Switzerland
- SectorsHealthcare
- Email••••••••
- Website alveolix.com
- Social LinkedIn
- Legal Name Alveolix Ag
- Investors
Products & Services of AlveoliX
AlveoliX offers a comprehensive portfolio of products and services, including AX Barrier-on-Chip System, AX Lung-on-Chip System, and AX Biomodels.
Simulates organ barriers for drug testing and research applications.
Mimics lung environments to study respiratory drug effects.
Provides models inspired by nature for complex human body emulation.
Funding Insights of AlveoliX
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of AlveoliX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in AlveoliX
AlveoliX has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Eureka Network.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Business management consulting services are offered to clients. | 1985 | eurekanetwork.org | Brussels, Belgium |
Investor details for AlveoliX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AlveoliX
4 people are tracked at AlveoliX (2 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Nina Hobi | Co-CEO & Scientific Director | Leadership |
Andreas Hugi | CTO | Leadership |
Laurène Froment | Biologist And Lab Manager | Team |
Giulia Raggi | Operations Manager & Scientific Project Lead | Team |
Complete people profiles for AlveoliX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AlveoliX
2 dated milestones of AlveoliX across 4 years, from founding to its latest funding, stage changes and deals.
- Founded AlveoliX is founded.
- Funding First funding round.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alveolix
Complete news archive for AlveoliX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AlveoliX
AlveoliX was founded in 2015 and raised its 1st funding round 4 years after it was founded.
AlveoliX is headquartered in Bern, Switzerland. It is registered at Bern, Bern, Switzerland.
Developer of organ-on-chip technologies to enable more efficient drug development. The lead product Lung-on-Chip system is an in-vitro model that closely mimics the biophysical characteristics of the lung, including the mechanical stress induced by respiration. This model is expected to best predict the effects of respiratory drug candidates in humans.
AlveoliX offers AX Barrier-on-Chip System, AX Lung-on-Chip System, and AX Biomodels.
AlveoliX has 1 investor. Key investors include Eureka Network.
AlveoliX operates through Alveolix Ag.